2-mt63

SARS-CoV-2-IN-63 (Compound R3e) serves as an inhibitor of SARS-CoV-2 replication, demonstrating low cytotoxicity. It effectively suppresses viral replication within Vero E6 cells and Calu-3 cells, yielding half-maximal effective concentration (EC50) values of 1.99 μM and 1.92 μM, respectively [1].

2-MT 63 is a novel TIE-2 kinase inhibitor that demonstrates unique and improved kinase selectivity compared to other inhibitors known to interact with TIE-2. 2-MT 63 has a good kinase selectivity profile in enzyme assays with >30-fold selectivity (typically much greater) against the tested kinases. Importantly, the profile includes selectivity against other targets of relevance for angiogenesis (KDR, PDGFR, EPHB4).

Mt KARI-IN-2 (compound 5b) is a highly effective inhibitor of Mycobacterium tuberculosis ketol-acid reductoisomerase (Mtb KARI), with a Ki value of 2.02 μM. This compound also exhibits inhibitory activity against Mtb H37Rv, with a MIC value of 0.78 μM. Moreover, Mt KARI-IN-2 demonstrates low cytotoxicity, as evidenced by a HEK IC 50 greater than 86 μg/mL [1].

MT 63-78 is a specific and effective direct AMPK activator (EC50: 25 μM). MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects. MT 63–78 also causes cell mitotic arrest and apoptosis.